Nusinersen · Spinraza
RNA / oligonucleotide
Evidence outlook
Approved: Spinal Muscular Atrophy
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (2)
- Treatment of infantile spinal muscular atrophy
- Spinraza is indicated for the treatment of 5q Spinal Muscular Atrophy.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01839656 NCT01839656 · Spinal Muscular Atrophy The study was nonrandomized, open-label, and lacked a placebo or active comparator; it enrolled 21 participants, with 20 treated and analyzed. Its clinical motor milestone endpoint was reported descriptively by dose group, but no formal controlled primary comparison was applicable, so the findings provide limited evidence that nusinersen caused the observed improvements. Registry: NCT01839656 | 2 | Percent of Participants Who Achieved Improvement in Motor Milestones as Assessed by Section 2 of the HINE at the Last Visit (Day 1352 or Early Termination) 2017-08-21 | Percent of Participants Who Achieved Improvement in Motor Milestones as Assessed by Section 2 of the HINE at the Last Visit (Day 1352 or Early Termination): Nusinersen 6 mg 25 Percent of participants | Nusinersen 12 mg 68.8 Percent of participants | Weak signal | link ↗ |
View 3 more trials
ENDEAR NCT02193074 · Spinal Muscular Atrophy This was a randomized, quadruple-blind, sham-controlled trial in 121 treated infants. Both co-primary endpoints favored nusinersen: 51% of nusinersen-treated infants achieved a motor milestone response versus 0% with sham (p<0.0001), and nusinersen reduced the risk of death or permanent ventilation (hazard ratio 0.53, p=0.0046). Registry: NCT02193074 | 3 | Percentage of Motor Milestones Responders (assessed at the later of the Day 183, Day 302, or Day 394 study visits); Time to Death or Permanent Ventilation (Day 91, Day 182, Day 273, Day 364, Day 394) 2016-11-21 | Stopped early (terminated). Key figures are not recorded here. | Reliable signal | link ↗ |
CHERISH NCT02292537 · Spinal Muscular Atrophy This was a randomized, quadruple-blind, sham-controlled trial in 126 patients. The primary endpoint, change in the Hammersmith Functional Motor Scale-Expanded score, improved significantly more with nusinersen than sham (+3.9 vs -1.0 points, p<0.0000001). Registry: NCT02292537 | 3 | Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15 (Baseline and Month 15) 2017-02-20 | Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15 (Baseline and Month 15): Sham Procedure -1 scores on a scale (95% CI -2.5 to 0.5) | Nusinersen 3.9 scores on a scale (95% CI 3 to 4.9) | Reliable signal | link ↗ |
NURTURE NCT02386553 · Spinal Muscular Atrophy This was a single-group, open-label study of 25 participants without randomization, blinding, or a comparator arm. Although the primary endpoint was a clinical outcome, it was descriptive rather than a formal treatment comparison, and the reported primary analysis had too few events to estimate the median. Registry: NCT02386553 | 2 | Time to Death or Respiratory Intervention (Screening up to Day 2891) 2024-12-17 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Early phase / not applicable (4)
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other SMN2 pre-mRNA drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Spinal Muscular Atrophy: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Nusinersen (Spinraza): this drug | Approved | RNA / oligonucleotide | SMN2 pre-mRNA | Weak signal | NCT02292537: Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15 (Baseline and Month 15): Sham Procedure -1 scores on a scale (95% CI -2.5 to 0.5) | Nusinersen 3.9 scores on a scale (95% CI 3 to 4.9) NCT01839656: Percent of Participants Who Achieved Improvement in Motor Milestones as Assessed by Section 2 of the HINE at the Last Visit (Day 1352 or Early Termination): Nusinersen 6 mg 25 Percent of participants | Nusinersen 12 mg 68.8 Percent of participants | |
| Apitegromab (Isembyld) | Approved | Monoclonal antibody | Myostatin (pro/latent form) | not yet graded | No reviewed efficacy summary in this indication | |
| Risdiplam (Evrysdi) | Approved | Small molecule | SMN2 pre-mRNA | not yet graded | No reviewed efficacy summary in this indication | |
| Taldefgrobep Alfa | Phase 3 | Antibody-derived scaffold | Activin/myostatin type II receptor | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Spinraza (Nusinersen) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.